BioSpace News Archive

New Data From ARTISTRY-1 Trial Provide Additional Evidence of Therapeutic Potential of ALKS 4230 as Monotherapy and in Combination With Pembrolizumab in Multiple Tumor Types

StemBioSys, Inc. (StemBioSys) and CarTox, Inc. (Cartox) announced today the publication of research in Nature Scientific Reports demonstrating that CELLvo™ Matrix Plus, an extracellular matrix (ECM) technology derived from human perinatal stem cells,

Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces that it has been awarded Hong Kong Patent No. 1188285 entitled, METHODS AND REAGENTS FOR SIGNAL AMPLIFICATION.

As part of its commitment to fostering a diverse and inclusive culture, AmerisourceBergen, a global healthcare solutions leader, announced the appointment of Dr. Lonie Haynes as the company’s SVP and Chief Diversity & Inclusion Officer.

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced third quarter and year-to-date financial results for 2020.

Incyte (Nasdaq:INCY) today announced that abstracts highlighting data from its oncology portfolio will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, held virtually from November 11-14, 2020.

Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the presentation of new preclinical data on AO-176 at the SITC Annual Meeting 2020.

Verve Therapeutics , a biotech company pioneering gene editing medicines to treat cardiovascular disease, today announced two presentations highlighting gene editing as a potentially transformative therapeutic approach at the American Heart Association (AHA) Scientific Sessions 2020, taking place virtually November 13-17, 2020. Verve is developing one-time gene editing medicines to safely and precisely turn off a gene i

Istari Oncology, Inc., a clinical-stage biotechnology company, today announced Phase 1 clinical data of its lead product candidate, PVSRIPO, for the treatment of patients with anti-PD-1 refractory melanoma at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

UroGen Pharma Ltd.today announced financial results for the third quarter ended September 30, 2020 and provided an overview of the Company’s recent developments.